Oncternal Therapeutics Investor Relations Material
Latest events
Q2 2024
Oncternal Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Oncternal Therapeutics Inc
Access all reports
Oncternal Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing oncology therapies aimed at addressing cancers with critical unmet medical needs. Their diverse pipeline of treatments targets hematological malignancies and prostate cancer through multiple modalities. Their investigational product candidates include ONCT-808, an autologous CAR T cell therapy targeting ROR1 for patients with multiple hematologic and solid malignancies; ONCT-534, a Dual-Action Androgen Receptor Inhibitor (DAARI) for advanced prostate cancer; and Zilovertamab, a monoclonal antibody that inhibits the ROR1 protein expressed in various malignancies. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Key slides for Oncternal Therapeutics Inc
Corporate Presentation
Oncternal Therapeutics Inc
Corporate Presentation
Oncternal Therapeutics Inc
Latest articles
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
ONCT
Country
🇺🇸 United States